

Cornelis J A Punt

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7586164/publications.pdf>

Version: 2024-02-01

224
papers

17,520
citations

31902

53
h-index

15683

125
g-index

225
all docs

225
docs citations

225
times ranked

20250
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical Trial Endpoints in Metastatic Cancer: Using Individual Participant Data to Inform Future Trials Methodology. <i>Journal of the National Cancer Institute</i> , 2022, 114, 819-828.	3.0	2
2	Development and external validation of a prediction model for overall survival after resection of distal cholangiocarcinoma. <i>British Journal of Cancer</i> , 2022, 126, 1280-1288.	2.9	4
3	Long-Term Safety Data on S-1 Administered After Previous Intolerance to Capecitabine-Containing Systemic Treatment for Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2022, 21, 229-235.	1.0	4
4	Quality of Life and Survival of Metastatic Colorectal Cancer Patients Treated With Trifluridine-Tipiracil (QUALITAS). <i>Clinical Colorectal Cancer</i> , 2022, 21, 154-166.	1.0	6
5	External validation of the MSKCC nomogram to estimate five-year overall survival after surgery for stage III colon cancer in a Dutch population. <i>Acta Oncologica</i> , 2022, 61, 560-565.	0.8	0
6	Reply to R. Pham et al. <i>JCO Precision Oncology</i> , 2022, 6, e2200053.	1.5	0
7	Toxicity and efficacy of chronomodulated chemotherapy: a systematic review. <i>Lancet Oncology</i> , The, 2022, 23, e129-e143.	5.1	36
8	Systematic review and non-inferiority meta-analysis of randomised phase II/III trials on S-1-based therapy versus 5-fluorouracil- or capecitabine-based therapy in the treatment of patients with metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2022, 166, 73-86.	1.3	8
9	Serum-based measurements of stromal activation through ADAM12 associate with poor prognosis in colorectal cancer. <i>BMC Cancer</i> , 2022, 22, 394.	1.1	7
10	Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. <i>Lancet Oncology</i> , The, 2022, 23, 659-670.	5.1	282
11	Predictive value of chromosome 18q11.2-q12.1 loss for benefit from bevacizumab in metastatic colorectal cancer: A post hoc analysis of the randomised phase III trial AGITG-MAX. <i>International Journal of Cancer</i> , 2022, 151, 1166-1174.	2.3	1
12	External Validation of Two Established Clinical Risk Scores Predicting Outcome after Local Treatment of Colorectal Liver Metastases in a Nationwide Cohort. <i>Cancers</i> , 2022, 14, 2356.	1.7	3
13	Interobserver Variability in CT-based Morphologic Tumor Response Assessment of Colorectal Liver Metastases. <i>Radiology Imaging Cancer</i> , 2022, 4, e210105.	0.7	3
14	FOLFOXIRI + bevacizumab versus FOLFOX/FOLFIRI + bevacizumab in patients with initially unresectable colorectal liver metastases (CRLM) and right-sided and/or <i>RAS</i> and/or <i>BRAFV600E</i> -mutated primary tumor: Phase III CAIRO5 study of the Dutch Colorectal Cancer Group.. <i>Journal of Clinical Oncology</i> , 2022, 40, LBA3506-LBA3506.	0.8	8
15	Informing metastatic colorectal cancer patients by quantifying multiple scenarios for survival time based on real-life data. <i>International Journal of Cancer</i> , 2021, 148, 296-306.	2.3	27
16	Survival of patients with deficient mismatch repair metastatic colorectal cancer in the pre-immunotherapy era. <i>British Journal of Cancer</i> , 2021, 124, 399-406.	2.9	19
17	Advanced analytics and artificial intelligence in gastrointestinal cancer: a systematic review of radiomics predicting response to treatment. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1785-1794.	3.3	32
18	Phase II study evaluating trifluridine/tipiracil + bevacizumab and capecitabine + bevacizumab in first-line unresectable metastatic colorectal cancer (mCRC) patients who are noneligible for intensive therapy (TASCO1): Results of the final analysis on the overall survival.. <i>Journal of Clinical Oncology</i> , 2021, 39, 14-14.	0.8	4

#	ARTICLE	IF	CITATIONS
19	Impact of geography on prognostic outcomes of 21,509 patients with metastatic colorectal cancer enrolled in clinical trials: an ARCAD database analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110205.	1.4	3
20	Longitudinal effects of adjuvant chemotherapy and related neuropathy on health utility in stage II and III colon cancer patients: A prospective cohort study. <i>International Journal of Cancer</i> , 2021, 148, 2702-2711.	2.3	3
21	Model-based effectiveness and cost-effectiveness of risk-based selection strategies for adjuvant chemotherapy in Dutch stage II colon cancer patients. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482199571.	1.4	3
22	Conversion of a colorectal cancer guideline into clinical decision trees with assessment of validity. <i>International Journal for Quality in Health Care</i> , 2021, 33, .	0.9	11
23	Interaction Between Primary Tumor Resection, Primary Tumor Location, and Survival in Synchronous Metastatic Colorectal Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2021, 44, 315-324.	0.6	8
24	Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial. <i>Lancet Oncology, The</i> , 2021, 22, 665-677.	5.1	110
25	Chromosomal copy number heterogeneity predicts survival rates across cancers. <i>Nature Communications</i> , 2021, 12, 3188.	5.8	43
26	Limitations of the PRODIGE 7 trial. <i>Lancet Oncology, The</i> , 2021, 22, e174.	5.1	6
27	Pre-Operative Decitabine in Colon Cancer Patients: Analyses on WNT Target Methylation and Expression. <i>Cancers</i> , 2021, 13, 2357.	1.7	2
28	Perioperative Systemic Therapy vs Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Alone for Resectable Colorectal Peritoneal Metastases. <i>JAMA Surgery</i> , 2021, 156, 710-720.	2.2	34
29	Prognostic and Predictive Impact of Primary Tumor Sidedness for Previously Untreated Advanced Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1705-1713.	3.0	12
30	Early Cost-effectiveness Analysis of Risk-Based Selection Strategies for Adjuvant Treatment in Stage II Colon Cancer: The Potential Value of Prognostic Molecular Markers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 1726-1734.	1.1	0
31	Framing the potential of public frameshift peptides as immunotherapy targets in colon cancer. <i>PLoS ONE</i> , 2021, 16, e0251630.	1.1	5
32	Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 1995-2004.	0.8	291
33	Molecular subtype-specific efficacy of anti-EGFR therapy in colorectal cancer is dependent on the chemotherapy backbone. <i>British Journal of Cancer</i> , 2021, 125, 1080-1088.	2.9	10
34	Postoperative circulating tumour DNA is associated with pathologic response and recurrence-free survival after resection of colorectal cancer liver metastases. <i>EBioMedicine</i> , 2021, 70, 103498.	2.7	16
35	Treatment breaks in first line treatment of advanced colorectal cancer: An individual patient data meta-analysis. <i>Cancer Treatment Reviews</i> , 2021, 99, 102226.	3.4	8
36	Advanced image analytics predicting clinical outcomes in patients with colorectal liver metastases: A systematic review of the literature. <i>Surgical Oncology</i> , 2021, 38, 101578.	0.8	17

#	ARTICLE	IF	CITATIONS
37	Role of Up-Front Primary Tumor Resection and Tumor Sidedness in the Survival of Synchronous Metastatic Colon Cancer Patients. <i>Digestive Surgery</i> , 2021, 38, 283-289.	0.6	1
38	Sixty-Day Mortality of Patients With Metastatic Colorectal Cancer Randomized to Systemic Treatment vs Primary Tumor Resection Followed by Systemic Treatment. <i>JAMA Surgery</i> , 2021, 156, 1093.	2.2	34
39	<i>KRAS</i> A146 Mutations Are Associated With Distinct Clinical Behavior in Patients With Colorectal Liver Metastases. <i>JCO Precision Oncology</i> , 2021, 5, 1758-1767.	1.5	9
40	“I am busy surviving” - Views about physical exercise in older adults scheduled for colorectal cancer surgery. <i>Journal of Geriatric Oncology</i> , 2020, 11, 444-450.	0.5	38
41	The association between preoperative fatigue and instrumental activities in daily living with complications and length of hospital stay in patients undergoing colorectal surgery. <i>Aging Clinical and Experimental Research</i> , 2020, 32, 257-264.	1.4	3
42	From registration to publication: A study on Dutch academic randomized controlled trials. <i>Research Synthesis Methods</i> , 2020, 11, 218-226.	4.2	7
43	Estimating adjuvant treatment effects in Stage II colon cancer: Comparing the synthesis of randomized clinical trial data to real-world data. <i>International Journal of Cancer</i> , 2020, 146, 2968-2978.	2.3	8
44	Rapid stromal remodeling by short-term VEGFR2 inhibition increases chemotherapy delivery in esophagogastric adenocarcinoma. <i>Molecular Oncology</i> , 2020, 14, 704-720.	2.1	7
45	Efficacy and safety of FOLFIRINOX as salvage treatment in advanced biliary tract cancer: an open-label, single arm, phase 2 trial. <i>British Journal of Cancer</i> , 2020, 122, 634-639.	2.9	40
46	Phase II Feasibility and Biomarker Study of Neoadjuvant Trastuzumab and Pertuzumab With Chemoradiotherapy for Resectable Human Epidermal Growth Factor Receptor 2-Positive Esophageal Adenocarcinoma: TRAP Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 462-471.	0.8	44
47	Model-based evaluation of the cost effectiveness of 3 versus 6 months' adjuvant chemotherapy in high-risk stage II colon cancer patients. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482095411.	1.4	3
48	Efficacy and safety of systemic induction therapy in initially unresectable locally advanced intrahepatic and perihilar cholangiocarcinoma: A systematic review. <i>Cancer Treatment Reviews</i> , 2020, 91, 102110.	3.4	8
49	Adjuvant Systemic Chemotherapy vs Active Surveillance Following Up-front Resection of Isolated Synchronous Colorectal Peritoneal Metastases. <i>JAMA Oncology</i> , 2020, 6, e202701.	3.4	27
50	Conversion strategies with chemotherapy plus targeted agents for colorectal cancer liver-only metastases: A systematic review. <i>European Journal of Cancer</i> , 2020, 141, 225-238.	1.3	29
51	Duration of adjuvant treatment for patients with stage III colon cancer. <i>Lancet Oncology</i> , The, 2020, 21, 1545-1547.	5.1	1
52	Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. <i>New England Journal of Medicine</i> , 2020, 383, 2207-2218.	13.9	1,513
53	Evaluation of the performance of algorithms mapping EORTC QLQ-C30 onto the EQ-5D index in a metastatic colorectal cancer cost-effectiveness model. <i>Health and Quality of Life Outcomes</i> , 2020, 18, 240.	1.0	4
54	Practice Variation in the Adjuvant Treatment of Colon Cancer in the Netherlands: A Population-based Study. <i>Anticancer Research</i> , 2020, 40, 4331-4341.	0.5	4

#	ARTICLE	IF	CITATIONS
55	Interconnectivity between molecular subtypes and tumor stage in colorectal cancer. <i>BMC Cancer</i> , 2020, 20, 850.	1.1	14
56	Endothelium-Derived Extracellular Vesicles Associate with Poor Prognosis in Metastatic Colorectal Cancer. <i>Cells</i> , 2020, 9, 2688.	1.8	10
57	Diagnostic Strategies toward Clinical Implementation of Liquid Biopsy RAS/BRAF Circulating Tumor DNA Analyses in Patients with Metastatic Colorectal Cancer. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 1430-1437.	1.2	19
58	Management of cytotoxic chemotherapy-induced hand-foot syndrome. <i>Oncology Reviews</i> , 2020, 14, 442.	0.8	56
59	Advances in adjuvant therapy of biliary tract cancer: an overview of current clinical evidence based on phase II and III trials. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 151, 102975.	2.0	14
60	Modeling Personalized Adjuvant Treatment in Early stage colon cancer (PATTERN). <i>European Journal of Health Economics</i> , 2020, 21, 1059-1073.	1.4	5
61	Comparing Circulating Tumor Cell Counts with Dynamic Tumor Size Changes as Predictor of Overall Survival: A Quantitative Modeling Framework. <i>Clinical Cancer Research</i> , 2020, 26, 4892-4900.	3.2	5
62	Practice variation on hospital level in the systemic treatment of metastatic colorectal cancer in The Netherlands: a population-based study. <i>Acta Oncologica</i> , 2020, 59, 395-403.	0.8	6
63	The association between changes in muscle mass and quality of life in patients with metastatic colorectal cancer. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2020, 11, 919-928.	2.9	15
64	Tumour-derived extracellular vesicles in blood of metastatic cancer patients associate with overall survival. <i>British Journal of Cancer</i> , 2020, 122, 801-811.	2.9	52
65	Autologous monocyte-derived DC vaccination combined with cisplatin in stage III and IV melanoma patients: a prospective, randomized phase 2 trial. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 477-488.	2.0	42
66	Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative. <i>European Journal of Cancer</i> , 2020, 130, 63-71.	1.3	15
67	RAINFORST: a random forest approach to predict treatment benefit in data from (failed) clinical drug trials. <i>Bioinformatics</i> , 2020, 36, i601-i609.	1.8	20
68	Feasibility of switching to S-1 after other fluoropyrimidine-related cardiotoxicity during chemotherapy for solid tumors. <i>Journal of Clinical Oncology</i> , 2020, 38, 7037-7037.	0.8	2
69	Comparing Conventional Chemotherapy to Chronomodulated Chemotherapy for Cancer Treatment: Protocol for a Systematic Review. <i>JMIR Research Protocols</i> , 2020, 9, e18023.	0.5	6
70	Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer (COLOPEC): a multicentre, open-label, randomised trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 761-770.	3.7	211
71	Prognostic immunohistochemical biomarkers of chemotherapy efficacy in biliary tract cancer: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 141, 82-94.	2.0	11
72	Evaluation of Continuous Tumor-Size-Based End Points as Surrogates for Overall Survival in Randomized Clinical Trials in Metastatic Colorectal Cancer. <i>JAMA Network Open</i> , 2019, 2, e1911750.	2.8	6

#	ARTICLE	IF	CITATIONS
73	Trajectory of body mass and skeletal muscle indices and disease progression in metastatic colorectal cancer patients. <i>American Journal of Clinical Nutrition</i> , 2019, 110, 1395-1403.	2.2	15
74	Choosing the right strategy based on individualized treatment effect predictions: combination versus sequential chemotherapy in patients with metastatic colorectal cancer. <i>Acta Oncologica</i> , 2019, 58, 326-333.	0.8	3
75	Stromal-derived interleukin 6 drives epithelial-to-mesenchymal transition and therapy resistance in esophageal adenocarcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 2237-2242.	3.3	128
76	Phase I Dose Escalation Study with Expansion Cohort of the Addition of Nab-Paclitaxel to Capecitabine and Oxaliplatin (CapOx) as First-Line Treatment of Metastatic Esophagogastric Adenocarcinoma (ACTION Study). <i>Cancers</i> , 2019, 11, 827.	1.7	6
77	Genome-wide cell-free DNA fragmentation in patients with cancer. <i>Nature</i> , 2019, 570, 385-389.	13.7	764
78	Skeletal muscle mass loss and dose-limiting toxicities in metastatic colorectal cancer patients. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2019, 10, 803-813.	2.9	65
79	Factors Contributing to Cancer-Related Muscle Wasting During First-Line Systemic Treatment for Metastatic Colorectal Cancer. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz014.	1.4	10
80	Chemoradiation induces epithelial-to-mesenchymal transition in esophageal adenocarcinoma. <i>International Journal of Cancer</i> , 2019, 145, 2792-2803.	2.3	23
81	Implementation, participation and satisfaction rates of a web-based decision support tool for patients with metastatic colorectal cancer. <i>Patient Education and Counseling</i> , 2019, 102, 1331-1335.	1.0	9
82	Adjuvant hepatic arterial infusion pump chemotherapy and resection versus resection alone in patients with low-risk resectable colorectal liver metastases – the multicenter randomized controlled PUMP trial. <i>BMC Cancer</i> , 2019, 19, 327.	1.1	33
83	Updated Survival Analysis of the Randomized Phase III Trial of S-1 Versus Capecitabine in the First-Line Treatment of Metastatic Colorectal Cancer by the Dutch Colorectal Cancer Group. <i>Clinical Colorectal Cancer</i> , 2019, 18, e229-e230.	1.0	4
84	O200 10-YEAR FOLLOW-UP OF A RANDOMISED CONTROLLED TRIAL COMPARING NEOADJUVANT CHEMORADIOTHERAPY PLUS SURGERY VERSUS SURGERY ALONE FOR OESOPHAGEAL OR JUNCTIONAL CANCER (CROSS). <i>Ecological Management and Restoration</i> , 2019, 32, .	0.2	0
85	Levels of choline-containing compounds in normal liver and liver metastases of colorectal cancer as recorded by ¹ H MRS. <i>NMR in Biomedicine</i> , 2019, 32, e4035.	1.6	5
86	Long-term Oncological and Functional Outcomes of Chemoradiotherapy Followed by Organ-Sparing Transanal Endoscopic Microsurgery for Distal Rectal Cancer. <i>JAMA Surgery</i> , 2019, 154, 47.	2.2	151
87	Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project. <i>Journal of the National Cancer Institute</i> , 2018, 110, 638-648.	3.0	90
88	Prognostic value of primary tumour resection in synchronous metastatic colorectal cancer: Individual patient data analysis of first-line randomised trials from the ARCAD database. <i>European Journal of Cancer</i> , 2018, 91, 99-106.	1.3	61
89	Feasibility and effectiveness of trifluridine/tipiracil in metastatic colorectal cancer: real-life data from The Netherlands. <i>International Journal of Clinical Oncology</i> , 2018, 23, 482-489.	1.0	34
90	Evaluation of Guideline Adherence in Colorectal Cancer Treatment in The Netherlands: A Survey Among Medical Oncologists by the Dutch Colorectal Cancer Group. <i>Clinical Colorectal Cancer</i> , 2018, 17, 58-64.	1.0	26

#	ARTICLE	IF	CITATIONS
91	Reporting of patient characteristics and stratification factors in phase 3 trials investigating first-line systemic treatment of metastatic colorectal cancer: A systematic review. <i>European Journal of Cancer</i> , 2018, 96, 115-124.	1.3	2
92	Nationwide comprehensive gastro-intestinal cancer cohorts: the 3P initiative. <i>Acta Oncologica</i> , 2018, 57, 195-202.	0.8	55
93	Clinical Usefulness of Tools to Support Decision-making for Palliative Treatment of Metastatic Colorectal Cancer: A Systematic Review. <i>Clinical Colorectal Cancer</i> , 2018, 17, e1-e12.	1.0	20
94	Does portal vein embolization prior to liver resection influence the oncological outcomes – A propensity score matched comparison. <i>European Journal of Surgical Oncology</i> , 2018, 44, 108-114.	0.5	14
95	Pseudoprogession on bevacizumab treatment: tumor-dynamics in the modern era of systemic treatment for metastatic colorectal cancer. <i>Acta Oncologica</i> , 2018, 57, 681-682.	0.8	4
96	Loss of Chromosome 18q11.2-q12.1 Is Predictive for Survival in Patients With Metastatic Colorectal Cancer Treated With Bevacizumab. <i>Journal of Clinical Oncology</i> , 2018, 36, 2052-2060.	0.8	26
97	Effect of Neoadjuvant Chemoradiotherapy on Health-Related Quality of Life in Esophageal or Junctional Cancer: Results From the Randomized CROSS Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 268-275.	0.8	91
98	Copy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapy. <i>Nature Communications</i> , 2018, 9, 4112.	5.8	55
99	Matching the model with the evidence: comparing discrete event simulation and state-transition modeling for time-to-event predictions in a cost-effectiveness analysis of treatment in metastatic colorectal cancer patients. <i>Cancer Epidemiology</i> , 2018, 57, 60-67.	0.8	18
100	Tumour budding is associated with the mesenchymal colon cancer subtype and RAS/RAF mutations: a study of 1320 colorectal cancers with Consensus Molecular Subgroup (CMS) data. <i>British Journal of Cancer</i> , 2018, 119, 1244-1251.	2.9	57
101	Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group. <i>European Journal of Cancer</i> , 2018, 100, 35-45.	1.3	29
102	Impact of different palliative systemic treatments on skeletal muscle mass in metastatic colorectal cancer patients. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2018, 9, 909-919.	2.9	42
103	Real-world cost-effectiveness of cetuximab in the third-line treatment of metastatic colorectal cancer based on patient chart review in the Netherlands. <i>Health Economics Review</i> , 2018, 8, 13.	0.8	10
104	Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC-1): A randomized, controlled, multicenter phase III trial. <i>Journal of Clinical Oncology</i> , 2018, 36, LBA4002-LBA4002.	0.8	120
105	Bevacizumab-based first-line chemotherapy in elderly patients with metastatic colorectal cancer: an individual patient data based meta-analysis. <i>Oncotarget</i> , 2018, 9, 10272-10283.	0.8	7
106	The first steps in the evaluation of a "black-box" decision support tool: a protocol and feasibility study for the evaluation of Watson for Oncology. <i>Journal of Clinical and Translational Research</i> , 2018, 3, 411-423.	0.3	4
107	Keeping track of all ongoing colorectal cancer trials using a mobile application: Usability and satisfaction results of the Dutch Colorectal Cancer Group Trials application. <i>Journal of Clinical and Translational Research</i> , 2018, 3, 435-440.	0.3	0
108	Tolerability of the oral fluoropyrimidine S-1 after hand-foot syndrome-related discontinuation of capecitabine in western cancer patients. <i>Acta Oncologica</i> , 2017, 56, 1023-1026.	0.8	9

#	ARTICLE	IF	CITATIONS
109	Cost-effectiveness of capecitabine and bevacizumab maintenance treatment after first-line induction treatment in metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2017, 75, 204-212.	1.3	24
110	How health-related quality of life assessment should be used in advanced colorectal cancer clinical trials. <i>Annals of Oncology</i> , 2017, 28, 2077-2085.	0.6	30
111	Disclosing the Uncertainty Associated with Prognostic Estimates in Breast Cancer. <i>Medical Decision Making</i> , 2017, 37, 179-192.	1.2	39
112	Case series of patients treated with the oral fluoropyrimidine S-1 after capecitabine-induced coronary artery vasospasm. <i>European Journal of Cancer</i> , 2017, 81, 130-134.	1.3	14
113	Quality assurance of the PREOPANC trial (2012-003181-40) for preoperative radiochemotherapy in pancreatic cancer. <i>Strahlentherapie Und Onkologie</i> , 2017, 193, 630-638.	1.0	7
114	Randomized phase III trial of S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer: SALTO study by the Dutch Colorectal Cancer Group. <i>Annals of Oncology</i> , 2017, 28, 1288-1293.	0.6	58
115	Incidence of capecitabine-related cardiotoxicity in different treatment schedules of metastatic colorectal cancer: A retrospective analysis of the CAIRO studies of the Dutch Colorectal Cancer Group. <i>European Journal of Cancer</i> , 2017, 76, 93-99.	1.3	54
116	From tumour heterogeneity to advances in precision treatment of colorectal cancer. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 235-246.	12.5	466
117	Survival after associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) for advanced colorectal liver metastases: A case-matched comparison with palliative systemic therapy. <i>Surgery</i> , 2017, 161, 909-919.	1.0	51
118	Regional and inter-hospital differences in the utilisation of liver surgery for patients with synchronous colorectal liver metastases in the Netherlands. <i>European Journal of Cancer</i> , 2017, 71, 109-116.	1.3	12
119	Evaluating the scientific basis of quality indicators in colorectal cancer care: A systematic review. <i>European Journal of Cancer</i> , 2017, 86, 166-177.	1.3	12
120	Direct detection of early-stage cancers using circulating tumor DNA. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	808
121	Clinicopathological factors influencing outcome in metastatic colorectal cancer patients treated with fluoropyrimidine and bevacizumab maintenance treatment vs observation: an individual patient data meta-analysis of two phase 3 trials. <i>British Journal of Cancer</i> , 2017, 117, 1768-1776.	2.9	10
122	Maintenance treatment with capecitabine and bevacizumab versus observation in metastatic colorectal cancer: updated results and molecular subgroup analyses of the phase 3 CAIRO3 study. <i>Annals of Oncology</i> , 2017, 28, 2128-2134.	0.6	61
123	Ethnic differences in colon cancer care in the Netherlands: a nationwide registry-based study. <i>BMC Cancer</i> , 2017, 17, 312.	1.1	4
124	Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	466
125	Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancérologie Digestive Database. <i>Journal of Clinical Oncology</i> , 2017, 35, 1929-1937.	0.8	37
126	Can we save the rectum by watchful waiting or transanal microsurgery following (chemo) radiotherapy versus total mesorectal excision for early rectal cancer (STAR-TREC study)? protocol for a multicentre, randomised feasibility study. <i>BMJ Open</i> , 2017, 7, e019474.	0.8	87

#	ARTICLE	IF	CITATIONS
127	Impact of tumor location on outcomes in patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG): An interim analysis from the prospective, observational CORRELATE study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 3567-3567.	0.8	3
128	Colorectal cancer at high risk of peritoneal metastases: long term outcomes of a pilot study on adjuvant laparoscopic HIPEC and future perspectives. <i>Oncotarget</i> , 2017, 8, 51200-51209.	0.8	22
129	Direct inhibition of STAT signaling by platinum drugs contributes to their anti-cancer activity. <i>Oncotarget</i> , 2017, 8, 54434-54443.	0.8	13
130	Decoy receptor 1 (DCR1) promoter hypermethylation and response to irinotecan in metastatic colorectal cancer. <i>Oncotarget</i> , 2017, 8, 63140-63154.	0.8	19
131	Evaluation of an oral uracil loading test to identify DPD-deficient patients using a limited sampling strategy. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 553-561.	1.1	26
132	<i>WRN</i> Promoter CpG Island Hypermethylation Does Not Predict More Favorable Outcomes for Patients with Metastatic Colorectal Cancer Treated with Irinotecan-Based Therapy. <i>Clinical Cancer Research</i> , 2016, 22, 4612-4622.	3.2	9
133	Oral drugs in the treatment of metastatic colorectal cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1351-1361.	0.9	21
134	T-cell Landscape in a Primary Melanoma Predicts the Survival of Patients with Metastatic Disease after Their Treatment with Dendritic Cell Vaccines. <i>Cancer Research</i> , 2016, 76, 3496-3506.	0.4	33
135	Reduced respiratory motion artifacts using structural similarity in fast 2D dynamic contrast enhanced MRI of liver lesions. <i>NMR in Biomedicine</i> , 2016, 29, 1526-1535.	1.6	1
136	Adjuvant Dendritic Cell Vaccination in High-Risk Uveal Melanoma. <i>Ophthalmology</i> , 2016, 123, 2265-2267.	2.5	44
137	Challenging the dogma of colorectal peritoneal metastases as an untreatable condition: Results of a population-based study. <i>European Journal of Cancer</i> , 2016, 65, 113-120.	1.3	45
138	Prospective Dutch colorectal cancer cohort: an infrastructure for long-term observational, prognostic, predictive and (randomized) intervention research. <i>Acta Oncologica</i> , 2016, 55, 1273-1280.	0.8	62
139	The prognostic value of WHO performance status in relation to quality of life in advanced colorectal cancer patients. <i>European Journal of Cancer</i> , 2016, 66, 138-143.	1.3	33
140	Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. <i>Lancet Oncology</i> , The, 2016, 17, 1709-1719.	5.1	442
141	Significant increase of synchronous disease in first-line metastatic colorectal cancer trials: Results of a systematic review. <i>European Journal of Cancer</i> , 2016, 69, 166-177.	1.3	12
142	A multi-centred randomised trial of radical surgery versus adjuvant chemoradiotherapy after local excision for early rectal cancer. <i>BMC Cancer</i> , 2016, 16, 513.	1.1	76
143	RE: Effects of adjuvant chemotherapy on recurrence, survival and quality of life in stage II colon cancer patients: a 24-month follow-up. <i>Supportive Care in Cancer</i> , 2016, 24, 4079-4080.	1.0	0
144	Adjuvant dendritic cell vaccination induces tumor-specific immune responses in the majority of stage III melanoma patients. <i>Oncolmmunology</i> , 2016, 5, e1191732.	2.1	17

#	ARTICLE	IF	CITATIONS
145	Preoperative radiochemotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC trial): study protocol for a multicentre randomized controlled trial. <i>Trials</i> , 2016, 17, 127.	0.7	131
146	Management of liver metastases in colorectal cancer patients: A retrospective case-control study of systemic therapy versus liver resection. <i>European Journal of Cancer</i> , 2016, 59, 13-21.	1.3	50
147	Favorable overall survival in stage III melanoma patients after adjuvant dendritic cell vaccination. <i>OncImmunology</i> , 2016, 5, e1057673.	2.1	67
148	Prophylactic vaccines are potent activators of monocyte-derived dendritic cells and drive effective anti-tumor responses in melanoma patients at the cost of toxicity. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 327-339.	2.0	50
149	Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic Cells. <i>Clinical Cancer Research</i> , 2016, 22, 2155-2166.	3.2	211
150	Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database. <i>Journal of Clinical Oncology</i> , 2016, 34, 144-150.	0.8	116
151	Randomized phase 3 study of S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer (mCRC): The SALTO study of the Dutch Colorectal Cancer Group.. <i>Journal of Clinical Oncology</i> , 2016, 34, 3640-3640.	0.8	1
152	Limited effect of lymph node status on the metastatic pattern in colorectal cancer. <i>Oncotarget</i> , 2016, 7, 31699-31707.	0.8	27
153	The CAIRO4 study: The role of surgery of the primary tumour with few or absent symptoms in patients with synchronous unresectable metastases of colorectal cancer – A randomized phase III study of the Dutch Colorectal Cancer Group (DCCG).. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS782-TPS782.	0.8	0
154	Prognostic value of primary tumor resection in synchronous metastatic colorectal cancer (mCRC): Individual patient data (IPD) analysis of first-line randomized trials from the ARCAD database.. <i>Journal of Clinical Oncology</i> , 2016, 34, 658-658.	0.8	0
155	Multicenter feasibility study of chemoradiation, trastuzumab and pertuzumab in resectable HER2+ esophageal carcinoma: The TRAP study.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS4142-TPS4142.	0.8	0
156	Systemic Treatment: Maintenance Compared with Holiday. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , 85-90.	1.8	3
157	ABC-Transporter Expression Does Not Correlate with Response to Irinotecan in Patients with Metastatic Colorectal Cancer. <i>Journal of Cancer</i> , 2015, 6, 1079-1086.	1.2	11
158	Multimodality Imaging to Predict Response to Systemic Treatment in Patients with Advanced Colorectal Cancer. <i>PLoS ONE</i> , 2015, 10, e0120823.	1.1	33
159	EMAST Is Associated with a Poor Prognosis in Microsatellite Instable Metastatic Colorectal Cancer. <i>PLoS ONE</i> , 2015, 10, e0124538.	1.1	28
160	Maintenance treatment in metastatic colorectal cancer. <i>Lancet Oncology</i> , The, 2015, 16, e582-e583.	5.1	4
161	Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. <i>Lancet Oncology</i> , The, 2015, 16, 1090-1098.	5.1	1,861
162	Adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with colon cancer at high risk of peritoneal carcinomatosis; the COLOPEC randomized multicentre trial. <i>BMC Cancer</i> , 2015, 15, 428.	1.1	115

#	ARTICLE	IF	CITATIONS
163	Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. <i>Lancet</i> , The, 2015, 385, 1843-1852.	6.3	421
164	Timing of adjuvant chemotherapy and its relation to survival among patients with stage III colon cancer. <i>European Journal of Cancer</i> , 2015, 51, 2553-2561.	1.3	95
165	Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data. <i>Lancet Oncology</i> , The, 2015, 16, 1639-1650.	5.1	277
166	Treatment strategies in colorectal cancer patients with initially unresectable liver-only metastases, a study protocol of the randomised phase 3 CAIRO5 study of the Dutch Colorectal Cancer Group (DCCG). <i>BMC Cancer</i> , 2015, 15, 365.	1.1	59
167	RE: Generalizability of Trial Results to Elderly Medicare Patients With Advanced Solid Tumors. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv104-djv104.	3.0	0
168	Analysis of KRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 5469-5479.	3.2	152
169	Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial. <i>Annals of Oncology</i> , 2015, 26, 696-701.	0.6	302
170	Individual Patient Data Analysis of Progression-Free Survival Versus Overall Survival As a First-Line End Point for Metastatic Colorectal Cancer in Modern Randomized Trials: Findings From the Analysis and Research in Cancers of the Digestive System Database. <i>Journal of Clinical Oncology</i> , 2015, 33, 22-28.	0.8	87
171	Radiofrequency ablation (RFA) combined with chemotherapy for unresectable colorectal liver metastases (CRC LM): Long-term survival results of a randomized phase II study of the EORTC-NCRI CCSG-ALM Intergroup 40004 (CLOCC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 3501-3501.	0.8	54
172	Treatment strategies in colorectal cancer patients with initially unresectable liver-only metastases: The randomized phase III CAIRO5 study of the Dutch Colorectal Cancer Group.. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS3622-TPS3622.	0.8	2
173	High Prevalence and Clinical Relevance of Genes Affected by Chromosomal Breaks in Colorectal Cancer. <i>PLoS ONE</i> , 2015, 10, e0138141.	1.1	24
174	Trial-level association between response-based endpoints (RBEs) and progression-free (PFS)/overall survival (OS) in first-line therapy for metastatic colorectal cancer (mCRC) in the ARCAD database.. <i>Journal of Clinical Oncology</i> , 2015, 33, 666-666.	0.8	1
175	Calculators for overall survival (OS) and progression-free survival (PFS) in metastatic colorectal cancer (mCRC): Construction from 19,678 ARCAD patients.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3555-3555.	0.8	0
176	The CAIRO4 study: The role of surgery of the primary tumour with few or absent symptoms in patients with synchronous unresectable metastases of colorectal cancer—A randomized phase III study of the Dutch Colorectal Cancer Group (DCCG).. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS3630-TPS3630.	0.8	0
177	Chromosomal Copy Number Aberrations in Colorectal Metastases Resemble Their Primary Counterparts and Differences Are Typically Non-Recurrent. <i>PLoS ONE</i> , 2014, 9, e86833.	1.1	21
178	Long Overall Survival After Dendritic Cell Vaccination in Metastatic Uveal Melanoma Patients. <i>American Journal of Ophthalmology</i> , 2014, 158, 939-947.e5.	1.7	53
179	Genomic landscape of metastatic colorectal cancer. <i>Nature Communications</i> , 2014, 5, 5457.	5.8	61
180	Excision Repair Cross-Complementation group 1 (ERCC1) C118T SNP does not affect cellular response to oxaliplatin. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2014, 759, 37-44.	0.4	11

#	ARTICLE	IF	CITATIONS
181	A phase II study of cediranib as palliative treatment in patients with symptomatic malignant ascites or pleural effusion. <i>Targeted Oncology</i> , 2014, 9, 331-338.	1.7	13
182	The effect of the UGT1A1*28 allele on survival after irinotecan-based chemotherapy: a collaborative meta-analysis. <i>Pharmacogenomics Journal</i> , 2014, 14, 424-431.	0.9	36
183	Local recurrence rates after radiofrequency ablation or resection of colorectal liver metastases. Analysis of the European Organisation for Research and Treatment of Cancer #40004 and #40983. <i>European Journal of Cancer</i> , 2014, 50, 912-919.	1.3	190
184	Intraperitoneal chemotherapy as adjuvant treatment to prevent peritoneal carcinomatosis of colorectal cancer origin: a systematic review. <i>British Journal of Cancer</i> , 2014, 111, 1112-1121.	2.9	41
185	Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies. <i>Clinical Cancer Research</i> , 2014, 20, 5322-5330.	3.2	561
186	Feasibility of adjuvant laparoscopic hyperthermic intraperitoneal chemotherapy in a short stay setting in patients with colorectal cancer at high risk of peritoneal carcinomatosis. <i>European Journal of Surgical Oncology</i> , 2014, 40, 1453-1458.	0.5	18
187	Final results and subgroup analyses of the phase 3 CAIRO3 study: Maintenance treatment with capecitabine + bevacizumab versus observation after induction treatment with chemotherapy + bevacizumab in metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 3504-3504.	0.8	15
188	Early predictors of prolonged overall survival (OS) in patients (pts) on first-line chemotherapy (CT) for metastatic colorectal cancer (mCRC): An ARCAD study with individual patient data (IPD) on 10,962 pts.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3538-3538.	0.8	2
189	Updated analysis of KRAS/NRAS and BRAF mutations in study 20050181 of panitumumab (pmab) plus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 3568-3568.	0.8	53
190	A phase II randomized, placebo controlled study to evaluate the efficacy of the combination of gemcitabine, erlotinib, and metformin in patients with locally advanced or metastatic pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 4021-4021.	0.8	5
191	Analysis of KRAS/NRAS mutations in phase 3 study 20050181 of panitumumab (pmab) plus FOLFIRI versus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2014, 32, LBA387-LBA387.	0.8	24
192	Final results and subgroup analyses of the phase 3 CAIRO3 study: Maintenance treatment with capecitabine and bevacizumab versus observation after induction treatment with chemotherapy and bevacizumab in metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2014, 32, LBA388-LBA388.	0.8	16
193	Statin Use Is Not Associated with Improved Progression Free Survival in Cetuximab Treated KRAS Mutant Metastatic Colorectal Cancer Patients: Results from the CAIRO2 Study. <i>PLoS ONE</i> , 2014, 9, e112201.	1.1	31
194	Sensitivity and specificity of an oral uracil-loading test dose for screening for DPD deficiency.. <i>Journal of Clinical Oncology</i> , 2014, 32, 11101-11101.	0.8	0
195	Body mass index (BMI) as prognostic in metastatic colorectal cancer (mCRC): A pooled analysis of 21 first-line trials in the ARCAD database.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3537-3537.	0.8	0
196	Radiological heterogeneity in response to chemotherapy is associated with poor survival in patients with colorectal liver metastases. <i>European Journal of Cancer</i> , 2013, 49, 2486-2493.	1.3	38
197	Comparison of treatment outcome in metastatic colorectal cancer patients included in a clinical trial versus daily practice in The Netherlands. <i>Acta Oncologica</i> , 2013, 52, 950-955.	0.8	51
198	Maintenance treatment with capecitabine and bevacizumab versus observation after induction treatment with chemotherapy and bevacizumab in metastatic colorectal cancer (mCRC): The phase III CAIRO3 study of the Dutch Colorectal Cancer Group (DCCG).. <i>Journal of Clinical Oncology</i> , 2013, 31, 3502-3502.	0.8	29

#	ARTICLE	IF	CITATIONS
199	Individual patient data (IPD) analysis of progression-free survival (PFS) versus overall survival (OS) as an endpoint for metastatic colorectal cancer (mCRC) in modern trials: Findings from the 16,700 patients (pts) ARCAD database.. Journal of Clinical Oncology, 2013, 31, 3533-3533.	0.8	2
200	Association of DNA promoter hypermethylation of decoy receptor 1 (DCR1) with poor response to irinotecan in metastatic colorectal cancer.. Journal of Clinical Oncology, 2013, 31, 3552-3552.	0.8	0
201	Vaccination with mRNA-Electroporated Dendritic Cells Induces Robust Tumor Antigen-Specific CD4+ and CD8+ T Cells Responses in Stage III and IV Melanoma Patients. Clinical Cancer Research, 2012, 18, 5460-5470.	3.2	86
202	Skin-Test Infiltrating Lymphocytes Early Predict Clinical Outcome of Dendritic Cell-Based Vaccination in Metastatic Melanoma. Cancer Research, 2012, 72, 6102-6110.	0.4	50
203	Role of Circulating Tumor Cells in Metastatic Colorectal Cancer: Clinical Challenges and Opportunities. Current Colorectal Cancer Reports, 2012, 8, 186-191.	1.0	0
204	New developments in gastrointestinal cancer-ASCO 2012. Memo - Magazine of European Medical Oncology, 2012, 5, 266-268.	0.3	0
205	Prognostic Value of Resection of Primary Tumor in Patients with Stage IV Colorectal Cancer: Retrospective Analysis of Two Randomized Studies and a Review of the Literature. Indian Journal of Surgical Oncology, 2012, 3, 57-65.	0.3	1
206	Tumor hypoxia as a mechanism of resistance to bevacizumab in a murine model.. Journal of Clinical Oncology, 2012, 30, e13111-e13111.	0.8	1
207	Route of Administration Modulates the Induction of Dendritic Cell Vaccine-Induced Antigen-Specific T Cells in Advanced Melanoma Patients. Clinical Cancer Research, 2011, 17, 5725-5735.	3.2	158
208	Prognostic Value of Resection of Primary Tumor in Patients with Stage IV Colorectal Cancer: Retrospective Analysis of Two Randomized Studies and a Review of the Literature. Annals of Surgical Oncology, 2011, 18, 3252-3260.	0.7	158
209	Pharmacogenetic interaction analysis for the efficacy of systemic treatment in metastatic colorectal cancer. Annals of Oncology, 2011, 22, 1147-1153.	0.6	39
210	Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice. Journal of Clinical Investigation, 2011, 121, 3100-3108.	3.9	271
211	Clinicopathological features and outcome in advanced colorectal cancer patients with synchronous vs metachronous metastases. British Journal of Cancer, 2010, 103, 159-164.	2.9	131
212	A prospective monitoring of fatal serious adverse events (SAEs) in a Dutch Colorectal Cancer Group (DCCG) phase III trial (CAIRO) in patients with advanced colorectal cancer. Annals of Oncology, 2010, 21, 415-418.	0.6	9
213	The predictive and prognostic value of circulating endothelial cells in advanced colorectal cancer patients receiving first-line chemotherapy and bevacizumab. Annals of Oncology, 2010, 21, 2447-2448.	0.6	34
214	In situ Expression of Tumor Antigens by Messenger RNA-Electroporated Dendritic Cells in Lymph Nodes of Melanoma Patients. Cancer Research, 2009, 69, 2927-2934.	0.4	56
215	More is less-combining targeted therapies in metastatic colorectal cancer. Nature Reviews Clinical Oncology, 2009, 6, 731-733.	12.5	70
216	Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer. New England Journal of Medicine, 2009, 360, 563-572.	13.9	1,243

#	ARTICLE	IF	CITATIONS
217	<i>BRAF</i> Mutation in Metastatic Colorectal Cancer. <i>New England Journal of Medicine</i> , 2009, 361, 98-99.	13.9	489
218	Endpoints in Adjuvant Treatment Trials: A Systematic Review of the Literature in Colon Cancer and Proposed Definitions for Future Trials. <i>Journal of the National Cancer Institute</i> , 2007, 99, 998-1003.	3.0	291
219	Randomised study of sequential versus combination chemotherapy with capecitabine, irinotecan and oxaliplatin in advanced colorectal cancer, an interim safety analysis. A Dutch Colorectal Cancer Group (DCCG) phase III study. <i>Annals of Oncology</i> , 2006, 17, 1523-1528.	0.6	32
220	Phenotypical and Functional Characterization of Clinical-Grade Dendritic Cells. , 2005, 109, 113-126.		28
221	Immunomonitoring Tumor-Specific T Cells in Delayed-Type Hypersensitivity Skin Biopsies After Dendritic Cell Vaccination Correlates With Clinical Outcome. <i>Journal of Clinical Oncology</i> , 2005, 23, 5779-5787.	0.8	174
222	New options and old dilemmas in the treatment of patients with advanced colorectal cancer. <i>Annals of Oncology</i> , 2004, 15, 1453-1459.	0.6	91
223	RFS2000 (9-nitrocamptothecin) in advanced small cell lung cancer, a phase II study of the EORTC New Drug Development Group. <i>European Journal of Cancer</i> , 2004, 40, 1332-1334.	1.3	14
224	Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study. <i>Lancet</i> , The, 2002, 360, 671-677.	6.3	216